Brave Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Brave Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,600	Closed	-$264K	–	153
2020 Q4	$264K	Hold	1,600	–	–	0.1%	100
2020 Q3	$228K	Buy	+1,600	New	+$198K	0.11%	88
2020 Q1	–	Sell	-1,660	Closed	-$248K	–	145
2019 Q4	$248K	Hold	1,660	–	–	0.13%	107
2019 Q3	$213K	Hold	1,660	–	–	0.12%	118
2019 Q2	$237K	Hold	1,660	–	–	0.13%	111
2019 Q1	$237K	Hold	1,660	–	–	0.13%	114
2018 Q4	$206K	Hold	1,660	–	–	0.14%	115
2018 Q3	$279K	Hold	1,660	–	–	0.14%	99
2018 Q2	$286K	Hold	1,660	–	–	0.17%	100
2018 Q1	$251K	Hold	1,660	–	–	0.15%	110
2017 Q4	$224K	Hold	1,660	–	–	0.12%	126
2017 Q3	$243K	Hold	1,660	–	–	0.13%	113
2017 Q2	$258K	Buy	+1,660	New	+$254K	0.14%	111
2016 Q4	–	Sell	-960	Closed	-$117K	–	237
2016 Q3	$117K	Buy	960 +810	+540%	+$109K	0.08%	161
2016 Q2	$21K	Hold	150	–	–	0.01%	284
2016 Q1	$20K	Hold	150	–	–	0.01%	293
2015 Q4	$21K	Buy	+150	New	+$20.8K	0.01%	290

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Brave Asset Management's JAZZ Position: Q1 2021 in Review

Brave Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 1,600 shares — an estimated $264K sold.

Brave Asset Management first reported a position in JAZZ in Q4 2015 and held it in 17 quarters. The position peaked at $286K in Q2 2018. 441 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

Brave Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Brave Asset Management sold 1,600 Jazz Pharmaceuticals shares in Q1 2021, an estimated $264K.
Brave Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 17 quarters.
Brave Asset Management's Jazz Pharmaceuticals position peaked at $286K in Q2 2018.
441 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Brave Asset Management's 13F filing for Q1 2021, filed 26 Apr 2021.